127 related articles for article (PubMed ID: 35633105)
1. Plasma trough concentration distribution and safety of high-dose teicoplanin for patients with augmented renal clearance.
Hu S; Wang T; You H; Chen S; Zhang T; Dong Y
J Clin Pharm Ther; 2022 Oct; 47(10):1548-1555. PubMed ID: 35633105
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections.
Zhou L; Gao Y; Cao W; Liu J; Guan H; Zhang H; Shi Y; Lv W; Cheng L
Infect Drug Resist; 2018; 11():29-36. PubMed ID: 29379306
[TBL] [Abstract][Full Text] [Related]
3. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.
Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y
Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731
[TBL] [Abstract][Full Text] [Related]
6. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
[TBL] [Abstract][Full Text] [Related]
7. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis.
Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y
J Clin Pharm Ther; 2021 Jun; 46(3):622-632. PubMed ID: 33547647
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of vancomycin for appropriate dosing in severe infective patients with augmented renal clearance].
Liu N; Zhang B; Liu Y; Tang J; Dong D; Gu Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):646-651. PubMed ID: 30045791
[TBL] [Abstract][Full Text] [Related]
9. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
[TBL] [Abstract][Full Text] [Related]
10. Model-based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non-complicated methicillin-resistant staphylococcus aureus infection.
Zhang XS; Chen YL; Wang YZ; Chen C; Chen YJ; Xu FM; Dai Y; Shi DW; Lin GY; Yu XB; Xiang DZ; Zhang CH
Br J Clin Pharmacol; 2024 Feb; 90(2):452-462. PubMed ID: 37749762
[TBL] [Abstract][Full Text] [Related]
11. Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 μg/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Yamada K; Tsuchida T; Otani N; Ide T; Takeda K; Nishi S; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
J Infect Chemother; 2022 Feb; 28(2):232-237. PubMed ID: 34844858
[TBL] [Abstract][Full Text] [Related]
12. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.
Pea F; Viale P; Candoni A; Pavan F; Pagani L; Damiani D; Casini M; Furlanut M
Clin Pharmacokinet; 2004; 43(6):405-15. PubMed ID: 15086277
[TBL] [Abstract][Full Text] [Related]
13. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
Wang JT; Liao HI; Wu Lin FL; Chang SC
Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
[TBL] [Abstract][Full Text] [Related]
14. Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance.
Yu YX; Lu J; Lu HD; Li L; Li JJ; Shi L; Duan LF; Zhuang ZW; Xue SD; Shen Y; Tang L
Eur J Hosp Pharm; 2022 Mar; 29(e1):e6-e14. PubMed ID: 33414258
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of teicoplanin concentrations and safety analysis in neonates.
Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
[TBL] [Abstract][Full Text] [Related]
17. Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies.
Wang YW; Hou HA; Lin CC; Lin HY; Chen PZ; Kuo CH; Chiu HH; Chuang CC; Chen YJ; Lin SW
Adv Ther; 2024 Jul; 41(7):2966-2977. PubMed ID: 38743241
[TBL] [Abstract][Full Text] [Related]
18. Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy.
Sato Y; Hiramatsu K; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Ogata M; Kadota JI; Itoh H
Chemotherapy; 2018; 63(1):29-34. PubMed ID: 29169153
[TBL] [Abstract][Full Text] [Related]
19. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J
Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288
[TBL] [Abstract][Full Text] [Related]
20. High-dose regimen to achieve novel target trough concentration in teicoplanin.
Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
